Sensitivity of Medicare Data to Identify Oncologists

Joan L Warren1, Michael J Barrett2, Dolly P White1

  • 1National Cancer Institute, Division of Cancer Control and Population Science, Bethesda, MD.

Abstract

Insights

The Center for Medicare and Medicaid Services (CMS) data captures most oncologists, but not all surgical oncologists (SOs). Combining CMS files improves identification of medical oncologists (MOs) and radiation oncologists (ROs).

Area of Science:

  • Health Services Research
  • Oncology
  • Data Science

Background:

  • Health services researchers often use Center for Medicare and Medicaid Services (CMS) or American Medical Association (AMA) data to identify oncologists.
  • The accuracy of CMS data for identifying oncologists has not been fully established.

Purpose of the Study:

  • To assess the completeness of CMS data resources for identifying oncologists compared to the AMA Physician Masterfile.
  • To determine the sensitivity of individual and combined CMS files in capturing different types of oncologists.

Main Methods:

  • Identified oncologists from three CMS data sources: physician claims, National Plan and Provider Enumeration System Registry, and Medicare Data on Provider Practice and Specialty file.
  • Linked CMS and AMA data using a unique physician identifier.
  • Calculated sensitivity for identifying oncologists, radiation oncologists (ROs), surgical oncologists (SOs), and medical oncologists (MOs).

Main Results:

  • Individual CMS files captured approximately 83% of oncologists from the AMA Masterfile; combined files captured 90.4%.
  • Combined CMS data identified 98.2% of ROs, 89.3% of MOs, and 70.1% of SOs.
  • CMS specialty data for ROs and SOs not identified as oncologists often corresponded to their AMA subspecialty (radiologists and surgeons, respectively).

Conclusions:

  • Combined CMS data effectively identifies most radiation and medical oncologists but has limitations for surgical oncologists.
  • The choice between AMA and CMS data depends on the research question and the specific oncologist subspecialty of interest.

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
580
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K